Ahmad A Tarhini

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    J Immunother 35:702-10. 2012
  2. ncbi Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
    Ahmad A Tarhini
    Assistant Professor of Medicine University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, RM 555 Pittsburgh, Pennsylvania, USA 1 412 648 6507 1 412 648 6579
    Expert Opin Drug Discov 4:587-603. 2009
  3. ncbi Tremelimumab: a review of development to date in solid tumors
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA 15232, USA
    Immunotherapy 5:215-29. 2013
  4. ncbi IFN-α in the treatment of melanoma
    Ahmad A Tarhini
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 189:3789-93. 2012
  5. ncbi Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    J Immunother 35:359-66. 2012
  6. ncbi Clinical and immunologic basis of interferon therapy in melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Ann N Y Acad Sci 1182:47-57. 2009
  7. ncbi A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
  8. ncbi Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, 5150 Centre Avenue, 5th Floor Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 9:505-14. 2007
  9. ncbi Releasing the brake on the immune system: ipilimumab in melanoma and other tumors
    Ahmad Tarhini
    University of Pittsburgh Cancer Institute, Pennsylvania 15232, USA
    Cancer Biother Radiopharm 25:601-13. 2010
  10. ncbi Oblimersen in the treatment of metastatic melanoma
    Ahmad A Tarhini
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, UPCI UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Future Oncol 3:263-71. 2007

Detail Information

Publications32

  1. ncbi Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA 15232, USA
    J Immunother 35:702-10. 2012
    ..T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg...
  2. ncbi Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
    Ahmad A Tarhini
    Assistant Professor of Medicine University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, RM 555 Pittsburgh, Pennsylvania, USA 1 412 648 6507 1 412 648 6579
    Expert Opin Drug Discov 4:587-603. 2009
    ..Phase I/II clinical trials have shown PF-3512676 to be well tolerated and to have antitumor activity as a single agent in patients with several types of advanced cancer, and to show promise as a vaccine adjuvant...
  3. ncbi Tremelimumab: a review of development to date in solid tumors
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA 15232, USA
    Immunotherapy 5:215-29. 2013
    ..The failure of the Phase III trial in melanoma is examined and factors affecting the possible future clinical development of tremelimumab are also explored...
  4. ncbi IFN-α in the treatment of melanoma
    Ahmad A Tarhini
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    J Immunol 189:3789-93. 2012
    ....
  5. ncbi Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    J Immunother 35:359-66. 2012
    ....
  6. ncbi Clinical and immunologic basis of interferon therapy in melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Ann N Y Acad Sci 1182:47-57. 2009
    ..Research of IFN-alpha in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response...
  7. ncbi A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
    ..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg...
  8. ncbi Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, 5150 Centre Avenue, 5th Floor Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 9:505-14. 2007
    ..Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer...
  9. ncbi Releasing the brake on the immune system: ipilimumab in melanoma and other tumors
    Ahmad Tarhini
    University of Pittsburgh Cancer Institute, Pennsylvania 15232, USA
    Cancer Biother Radiopharm 25:601-13. 2010
    ..Ipilimumab not only has a novel mechanism of action but demonstrates unique immune-related toxicities that require particular care in their recognition and treatment...
  10. ncbi Oblimersen in the treatment of metastatic melanoma
    Ahmad A Tarhini
    Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, UPCI UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Future Oncol 3:263-71. 2007
    ..This article reviews the biochemistry, pharmacodynamics and pharmacokinetics, safety and efficacy data related to oblimersen in melanoma...
  11. ncbi Neoadjuvant therapy for high-risk bulky regional melanoma
    Ahmad A Tarhini
    Department of Medicine and Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Surg Oncol 104:386-90. 2011
    ..This will simplify the evaluation of promising new combinations of agents with HDI to build on the clinical, immunologic, and molecular effect of this therapy for patients with melanoma...
  12. ncbi Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin
    Ahmad A Tarhini
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 17:6574-81. 2011
    ..We conducted a multicenter phase II study in patients with inoperable stage III or IV melanoma and no prior chemotherapy...
  13. ncbi Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Ave, Fifth Fl, Pittsburgh, PA 15232, USA
    J Clin Oncol 30:322-8. 2012
    ..We tested the hypothesis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic mechanisms would overcome tumor immune tolerance and lead to significant and durable clinical responses...
  14. ncbi Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
    Ahmad A Tarhini
    University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Melanoma and Skin Cancer Program, Department of Medicine, UPMC Cancer Pavilion, 5150 Centre Avenue, Room 559, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 8:1583-93. 2008
    ..Additional Phase II and III studies in combination with other agents will assess antitumor activity in multiple tumor types as well as attempt to identify patient populations most likely to respond...
  15. ncbi Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...
  16. ncbi Cutaneous melanoma: available therapy for metastatic disease
    Ahmad A Tarhini
    Division of Hematology Oncology, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5th Floor, 5150 Center Avenue, Pittsburgh, PA 15232, USA
    Dermatol Ther 19:19-25. 2006
    ..A number of novel therapeutic agents are undergoing active clinical investigation...
  17. ncbi A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Cancer 113:1632-40. 2008
    ..Previous biochemotherapy regimens for metastatic melanoma have required attenuated dosages of interleukin 2 (IL-2) that may have compromised efficacy...
  18. ncbi First International Symposium on Melanoma and Other Cutaneous Malignancies
    Ahmad A Tarhini
    Division of Hematology/Oncology, UPMC Cancer Pavilion, 5th Floor, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Expert Opin Biol Ther 4:1541-6. 2004
    ..Sessions also included case-based learning and devoted ample time to providing 'how to' information for practising physicians...
  19. ncbi Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Department of Medicine, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    Nat Clin Pract Oncol 5:2-3. 2008
  20. ncbi Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    J Clin Oncol 25:3802-7. 2007
    ..We conducted a phase II trial of high-dose bolus (HDB) interleukin-2 (IL-2) in patients with metastatic melanoma who had experienced progression after biochemotherapy (BCT)...
  21. ncbi Immunotherapy of cancer in 2012
    John M Kirkwood
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213, USA
    CA Cancer J Clin 62:309-35. 2012
    ....
  22. ncbi Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer 112:1131-8. 2008
    ..Arsenic trioxide (ATO) cytotoxicity and apoptosis induction has been demonstrated with numerous cancer cell lines, including human melanoma...
  23. ncbi Interleukin-2 for the treatment of melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Pittsburgh, PA 15232, USA
    Curr Opin Investig Drugs 6:1234-9. 2005
    ..Newer, innovative approaches such as IL-2 gene therapy and strategies to ameliorate the toxicity of this agent are now being explored in clinical trials...
  24. ncbi Novel agents in development for the treatment of melanoma
    Ahmad A Tarhini
    Division of Medical Oncology and Hematology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Expert Opin Investig Drugs 14:885-92. 2005
    ....
  25. ncbi A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
    Ahmad A Tarhini
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 2584, USA
    Cancer 115:859-68. 2009
    ..Phase 1 studies demonstrated evidence of recombinant human IL-18 (rhIL-18)-mediated immunomodulatory and clinical activity, and defined a biologically active dose range...
  26. ncbi Management of brain metastases in patients with melanoma
    Ahmad A Tarhini
    Department of Medicine and Division of Hematology/Oncology, Melanoma Center, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Curr Opin Oncol 16:161-6. 2004
    ..An urgent need exists to further define these treatments in the context of randomized trials, several of which are under way in the United States and abroad...
  27. ncbi Adjuvant high-dose interferon-alpha therapy for high-risk melanoma
    John M Kirkwood
    Division of Medical Oncology, University of Pittsburgh, 200 Lothrop Street, 15123 Pittsburg, Pennsylvania
    Forum (Genova) 13:127-40; quiz 187-8. 2003
    ..We also present selected ongoing trials testing potential future therapies that may prove effective for patients with high-risk resected melanoma...
  28. ncbi Adjuvant therapy for melanoma
    Diwakar Davar
    Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Cancer J 18:192-202. 2012
    ..At present, several trials investigating combinations of novel agents with existing immunomodulators are underway...
  29. ncbi Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 27:38-44. 2009
    ..We evaluated adjuvant trial E1694 to more precisely define the prognostic significance of serum S100B in patients with high-risk resected melanoma...
  30. ncbi Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma?
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, PA 15213, USA
    Nat Clin Pract Oncol 2:240-1. 2005
  31. ncbi Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach
    Diwakar Davar
    Division of General Internal Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Clin Dermatol 31:237-50. 2013
    ....
  32. ncbi Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b"
    Ahmad A Tarhini
    Oncologist 11:538-9; author reply 539-40. 2006